Viewing Study NCT00506168


Ignite Creation Date: 2025-12-24 @ 5:37 PM
Ignite Modification Date: 2025-12-29 @ 3:56 AM
Study NCT ID: NCT00506168
Status: TERMINATED
Last Update Posted: 2007-07-25
First Post: 2007-07-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
Sponsor: National Cancer Center, Korea
Organization:

Study Overview

Official Title: Phase II Study of Irinotecan in Combination With Capecitabine in Previously Untreated Patients With Metastatic Colorectal Cancer
Status: TERMINATED
Status Verified Date: 2007-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: The study drugs are not covered anymore by insurance.
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.
Detailed Description: This is a single center, single arm, open-label, phase II study to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.

Patients younger then 65 will be treated with irinotecan 100 mg/m2 on day 1 and 8 and capecitabine 1,000mg/m2 twice daily from day 1 to 14 every 3 weeks.For patiens equal to or older then 65, doses of irinotecan and capecitabine will be reduced to 60 mg/m2 and 750 mg/2, respectively.

Response assessment will be performed every 3 cycles of chemotherapy.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: